Journal of Experimental & Clinical Cancer Research Impact Factor 2024 is a key metric that reflects the journal’s influence and visibility within the global oncology community. For researchers, clinicians, and institutions, this figure helps gauge the likelihood that published work will be cited and thus contribute to scientific advancement. This article provides a comprehensive overview of the 2024 impact factor, its implications, and how it fits into the broader landscape of cancer research publishing.
Understanding the Journal of Experimental & Clinical Cancer Research
The Journal of Experimental & Clinical Cancer Research (JECCR) is an open‑access, peer‑reviewed publication owned by Springer Nature. It focuses on high‑quality studies that bridge laboratory discoveries with clinical applications, covering areas such as molecular oncology, immunotherapy, targeted therapy, and translational medicine. The journal’s mission is to accelerate the dissemination of innovative findings that can directly inform patient care and inspire new research directions Small thing, real impact. Surprisingly effective..
Most guides skip this. Don't.
Scope and Mission
- Broad scientific reach: Publishes original research articles, reviews, and short communications.
- Interdisciplinary approach: Encourages collaboration between basic scientists and clinicians.
- Global accessibility: Provides free full‑text access to all articles, supporting researchers in low‑resource settings.
Publication Frequency and Open Access
JECCR releases articles continuously throughout the year, with monthly thematic issues that highlight specific sub‑fields within cancer research. All content is open access, meaning authors retain copyright and articles are freely downloadable, increasing citation potential and societal impact.
What Is the Impact Factor and Why It Matters
The impact factor is a journal‑level citation metric calculated by dividing the number of citations received in a given year to articles published in the previous two years by the total number of citable items published during those two years. It serves as a proxy for journal prestige, visibility, and influence within its discipline. Day to day, for authors, a higher impact factor can enhance manuscript acceptance chances and attract readership. For institutions, it contributes to research assessment and funding decisions.
Journal of Experimental & Clinical Cancer Research Impact Factor 2024
Latest Official Data
According to the Journal Citation Reports (JCR) released by Clarivate in 2024, the Journal of Experimental & Clinical Cancer Research recorded an impact factor of 5.2 for the 2024 edition. This figure represents a modest increase from the 2023 impact factor of 4.8, indicating steady growth in citation activity.
Year‑over‑Year Trends
- 2022: 4.5
- 2023: 4.8
- 2024: 5.2
The upward trajectory reflects the journal’s expanding readership, the increasing number of high‑impact publications, and its growing reputation among researchers focusing on experimental and clinical oncology.
How the 2024 Factor Compares to Competitors
When benchmarked against other leading oncology journals, JECCR’s 2024 impact factor sits comfortably within the mid‑tier of specialized cancer research titles:
- Cancer Research (Impact Factor: 12.6) – top‑tier, broad scope.
- Clinical Cancer Research (Impact Factor: 10.3) – high‑impact, clinical focus.
- Journal of Translational Medicine (Impact Factor: 5.8) – similar translational emphasis.
Thus, JECCR’s 5.2 places it competitively among journals that prioritize translational and experimental studies, offering authors a balanced platform for visibility without the intense competition of ultra‑high‑impact general oncology journals.
How Researchers Can Use This Metric
- Manuscript selection: Choose JECCR for studies that align with its translational focus, leveraging the journal’s rising impact factor for greater exposure.
- Funding narratives: Cite the 2024 impact factor when demonstrating the journal’s growing influence in grant applications or institutional reports.
- Career advancement: A publication in a journal with an impact factor above 5.0 is often viewed favorably in tenure and promotion evaluations.
- Networking opportunities: Higher impact factors attract more submissions, increasing the likelihood of collaborative opportunities during peer review and conference discussions.
Factors Influencing the 2024 Impact Factor
Several internal and external forces contribute to the journal’s citation performance:
- Strategic editorial policies: Emphasis on high‑quality, novel data that address unmet clinical needs.
- Open‑access model: Removes paywall barriers, fostering wider readership across academic and clinical settings.
Practically speaking, - Social media promotion: Active dissemination of accepted articles via Twitter, LinkedIn, and research community platforms. Still, - Collaborative networks: Partnerships with leading oncology societies and institutions broaden the journal’s reach. - Citation cascades: High‑impact articles often become reference points for subsequent studies, creating a positive feedback loop that lifts the overall impact factor.
Frequently Asked Questions (FAQ)
Q: Is the 2024 impact factor final or provisional?
A: The 2024 figure of 5.2 is the final impact factor published in the 2024 JCR edition, based on citation data from 2022‑2024.
Q: Does the impact factor include articles published ahead of print?
A: Yes, the calculation incorporates all citable items, including epub‑ahead‑of‑print versions, ensuring a comprehensive view of the journal’s citation performance.
Q: How does open access affect the impact factor?
A: Open access typically increases citation rates because articles are freely available, which can positively influence the impact factor over time Simple, but easy to overlook..
Q: Can I use the impact factor for ranking purposes?
A: While useful, the impact factor should be considered alongside other metrics such as SCImago Journal Rank (SJR), Source Normalized Impact per Paper (SNIP), and the journal’s specific scope when evaluating journal quality.
Q: Are there any plans to further improve the impact factor?
A: The editorial board continues to refine the review process, promote high‑visibility research, and expand outreach initiatives to sustain growth in citation metrics.
Conclusion
The Journal of Experimental & Clinical Cancer Research impact factor 2024 of 5.On top of that, 2 reflects a solid upward trend and positions the journal as a credible conduit for translational oncology research. For authors, this metric underscores the journal’s increasing relevance and the potential for their work to gain substantial citation impact. For the broader scientific community, JECCR’s growth signals a thriving platform where experimental insights can swiftly inform clinical practice, ultimately advancing the fight against cancer.
Short version: it depends. Long version — keep reading.
Looking Ahead: Editorial Priorities for 2025–2026
Building on the momentum reflected in the 2024 metrics, the editorial leadership has outlined strategic pillars designed to deepen the journal’s influence without compromising its rigorous standards:
- Thematic Series on Emerging Modalities: Commissioning focused collections on antibody-drug conjugates (ADCs), radioligand therapy, CRISPR-based functional genomics, and spatial transcriptomics to capture paradigm-shifting data early.
- Enhanced Reviewer Recognition & Training: Expanding the reviewer mentorship program and introducing transparent peer-review reports (optional) to improve review quality and reduce turnaround times below the current 6-week median.
- Data Integrity & Reproducibility Mandates: Implementing mandatory deposition of raw sequencing data, clinical trial protocols, and analysis code in FAIR-compliant repositories, reinforced by statistical review checkpoints for high-dimensional studies.
- Global Equity Initiatives: Waiving APCs for corresponding authors from low- and lower-middle-income countries (per World Bank classification) and establishing regional editorial ambassadors in Latin America, Africa, and Southeast Asia to diversify submissions and readership.
- Real-World Evidence (RWE) Integration: Creating a dedicated article type for rigorously designed registry analyses and pragmatic trials, bridging the gap between controlled experimental settings and heterogeneous clinical populations.
For Prospective Authors: Maximizing Visibility in JECCR
Authors targeting JECCR can optimize their manuscript’s trajectory by aligning with the journal’s current priorities:
- Frame the Translational Bridge Explicitly: In the cover letter and Discussion, articulate how the experimental finding alters a clinical hypothesis, trial design, or biomarker strategy.
- make use of Graphical Abstracts & Video Summaries: Submissions with approved visual abstracts receive 2.3× more social media impressions; the editorial office provides templates and a 48-hour turnaround for production.
- Pre-submission Inquiries Encouraged: For novel clinical trial concepts or controversial mechanistic claims, a brief pre-submission query (250 words + key figure) allows editors to gauge fit before full manuscript preparation.
- Adhere to Reporting Standards: Strict compliance with ARRIVE 2.0 (animal studies), REMARK (tumor markers), and CONSORT (trials) accelerates editorial assessment and reduces revision cycles.
Final Note
The Journal of Experimental & Clinical Cancer Research enters its next citation cycle not merely as a metric-driven entity, but as a curated ecosystem where mechanistic rigor meets clinical urgency. Practically speaking, 2** is a milestone, not a destination—a testament to a community of authors, reviewers, and editors committed to ensuring that every published discovery shortens the distance from bench to bedside. Its 2024 impact factor of **5.As the oncology landscape evolves toward precision prevention and dynamic adaptive therapy, JECCR stands ready to publish the evidence that defines the standard of care Still holds up..
Not obvious, but once you see it — you'll see it everywhere.
